# A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

> **NCT04465734** · PHASE3 · WITHDRAWN · sponsor: **Shanghai Henlius Biotech**

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** HLX10
- **DRUG:** HLX04
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04465734
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-15
- **Primary completion:** 2023-10-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04465734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04465734, "A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04465734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*